Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience.

ABSTRACT:

Introduction

Thyroid cancer is the most common endocrine malignancy. The outcomes of patients with relapsed thyroid cancer treated on early-phase clinical trials have not been systematically analyzed.

Patients and methods

We reviewed the records of consecutive patients with metastatic thyroid cancer referred to the Phase I Clinical Trials Program from March 2006 to April 2008. Best response was assessed by Response Evaluation Criteria in Solid Tumors.

Results

Fifty-six patients were identified. The median age was 55 yr (range 35-79 yr). Of 49 patients evaluable for response, nine (18.4%) had a partial response, and 16 (32.7%) had stable disease for 6 months or longer. The median progression-free survival was 1.12 yr. With a median follow-up of 15.6 months, the 1-yr su

SUBMITTER: Tsimberidou AM 

PROVIDER: S-EPMC2775645 | biostudies-literature | 2009 Nov

REPOSITORIES: biostudies-literature